Article

Daily Medication Pearl: Vericiguat for Heart Failure

Verquvo is a soluble guanylate cyclase stimulator indicated to reduce the risk of cardiovascular death and heart failure.

Medication Pearl of the Day: Vericiguat (Verquvo)

Vericiguat is a soluble guanylate cyclase (sGC) stimulator indicated to reduce the risk of cardiovascular death and heart failure (HF) emergency department visits following an initial hospitalization for HF or need for outpatient intravenous diuretics in adults with symptomatic chronic HF and ejection fraction less than 45%.

Insight:

  • Dosing: The starting dose of vericiguat is 2.5 mg orally once daily with food.
  • Dosage forms: Tablets: 2.5 mg, 5 mg, and 10 mg.
  • Adverse events: Most common adverse reactions reported in ≥5% are hypotension and anemia.
  • Drug interactions: PDE-5 Inhibitors: Concomitant use is not recommended.
  • Mechanism of action: Vericiguat is a stimulator of sGC, an important enzyme in the nitric oxide (NO) signaling pathway. By directly stimulating sGC, independently of and synergistically with NO, vericiguat augments levels of intracellular cGMP, leading to smooth muscle relaxation and vasodilation.

Sources:

verquvo_pi (merck.com)

verquov image - Google Search

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Image credit:  Artur | stock.adobe.com
Cardiovascular disease doctor or cardiologist holding red heart in clinic or hospital exam room office for csr professional medical service, cardiology health care and world heart health day concept - Image credit: Chinnapong | stock.adobe.com
Image credit: AwieDarwis | stock.adobe.com
Image credit: viperagp | stock.adobe.com
Image credit:  kitsawet | stock.adobe.com